{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["unresectable metastatic colorectal cancer"],"disease":["Unresectable Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2634263"],"location":["Japan"],"study_start_month":["9"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy","description":"Interventions: Regorafenib 40 mg tablets Regorafenib 120 mg od po. 3weeks on/1 week off Patients will continue study treatment until disease progression\nPrimary outcome(s): Disease control rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2015-09-15"},"accession":"2634263","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000018968"]}}